Health Technology Assessment

Cyclooxygenase-2 selective non-steroidal anti-inflammatory (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis or rheumatoid arthritis: a systematic review and economic evaluation

  • Type:
    Extended Research Article
  • Authors:
    Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, et al.
  • Journal:
    Health Technology Assessment
  • Issue:
    Volume: 12, Issue: 11
  • Published:
  • Citation:
    Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis or rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12(11). https://doi.org/10.3310/hta12110
  • DOI:
    https://doi.org/10.3310/hta12110
Crossmark status check

Toolkit

View Award

The full text of this issue is available as a PDF document from the Toolkit section on this page

We are currently working on improvements to this feature. Please check back soon for updates